Corona Remedies IPO
Corona Remedies IPO Details
-
Open Date
08 Dec 2025
-
Close Date
10 Dec 2025
-
Listing Date
15 Dec 2025
- IPO Price Range
₹ 1008 to ₹1062
- IPO Size
₹ 655.37 Cr
- Listing Exchange
BSE NSE
Corona Remedies IPO Timeline
Corona Remedies IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 8-Dec-2025 | 0.00 | 0.84 | 0.95 | 0.67 |
| 9-Dec-2025 | 1.76 | 28.34 | 6.86 | 9.93 |
| 10-Dec-2025 | 293.80 | 220.18 | 30.39 | 144.54 |
Last Updated: 10 December 2025 5:25 PM by 5paisa
Corona Remedies Limited, launching a ₹655. 37 Cr IPO, is a pharmaceutical company focused on women’s healthcare, cardiology, pain management, urology, and other key therapeutic areas. As of 30 June 2025, it offers 71 brands spanning cardio-diabeto, multispecialty, and nutrition-based segments. Supported by a pan-India network of 2,671 medical representatives across 22 states, the company engages effectively with healthcare professionals and hospitals, strengthening its presence in the Indian pharmaceutical market.
Established in: 2004
Managing Director: Niravkumar Kirtikumar Mehta
Ankur Kirtikumar Mehta
Peers:
| Metric | Corona Remedies Limited | Abbott India Limited | Alkem Laboratories Limited | Eris Lifesciences Limited |
GlaxoSmithKline Pharmaceuticals Limited |
|
Face Value (₹ per share) |
10.00 | 10.00 | 2.00 | 1.00 | 10.00 |
| P/E | - | 45.17 | 31.39 | 61.81 | 46.87 |
| Revenue from Operations (₹ Cr) | 1196.42 | 6409.15 | 12964.52 | 2893.64 | 3749.21 |
| Earnings Per Share (Basic) (₹) | 24.43 | 665.62 | 181.11 | 25.85 | 54.76 |
|
Earnings Per Share (Diluted) (₹) |
24.43 | 665.62 | 181.11 | 25.81 | 54.76 |
| Return on Net Worth (RoNW) (%) | 24.65 | 33.41 | 18.07 | 12.21 | 47.54 |
| NAV per equity share (₹) |
99.14 | 1992.14 | 1002.37 | 209.73 | 115.19 |
Corona Remedies Objectives
1. The company will cover BRLMs fees and commissions.
2. It intends to pay registrar-related fees promptly.
3. Selling and processing charges will also be settled.
4. Advertising and marketing costs will be fully addressed.
5. Additional regulatory and professional expenses will be managed.
Corona Remedies IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹655.37 Cr |
| Offer For Sale | ₹655.37 Cr |
| Fresh Issue | - |
Corona Remedies IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 14 | 14,112 |
| Retail (Max) | 13 | 182 | 1,93,284 |
| S-HNI (Min) | 14 | 196 | 1,97,568 |
| S-HNI (MAX) | 67 | 938 | 9,96,156 |
| B-HNI (Min) | 68 | 952 | 9,59,616 |
Corona Remedies IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 293.80 | 12,21,729 | 35,89,39,448 | 38,119.37 |
| Non-Institutional Buyers | 220.18 | 9,16,960 | 20,18,97,066 | 21,441.47 |
| bNII (bids above ₹10L) | 246.67 | 6,11,307 | 15,07,93,356 | 16,014.25 |
| sNII (bids below ₹10L) | 167.20 | 3,05,653 | 5,11,03,710 | 5,427.21 |
| Individual Investors (IND category bidding for 2 Lots) | 30.39 | 21,39,573 | 6,50,20,634 | 6,905.19 |
| Total** | 144.54 | 43,36,298 | 62,67,60,036 | 66,561.92 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 884.05 | 1014.47 | 1196.42 |
| EBITDA | 135.03 | 161.19 | 245.91 |
| PAT | 84.93 | 90.50 | 149.43 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 595.02 | 830.58 | 929.86 |
| Share Capital | 61.16 | 61.16 | 61.16 |
| Total Liabilities | 186.50 | 350.17 | 323.52 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 102.70 | 156.76 | 190.50 |
| Net Cash Generated From / (used in) Investing Activities | -50.25 | -266.64 | -83.84 |
| Net Cash Generated From / (used in) Financing Activities | -44.75 | 98.55 | -106.59 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 7.71 | -11.34 | 0.07 |
Strengths
1. Strong presence across multiple therapeutic segments.
2. Wide portfolio with 71 established brands.
3. Extensive pan-India medical representative network.
4. Deep engagement with healthcare professionals nationwide.
Weaknesses
1. Heavy dependence on domestic market performance.
2. Limited global footprint restricts growth opportunities.
3. Portfolio competition remains consistently intense.
4. High marketing costs impact profitability margins.
Opportunities
1. Rising demand for women’s healthcare treatments.
2. Expansion possible into underserved regional markets.
3. Growing focus on preventive health creates potential.
4. Diversification into newer specialties offers growth.
Threats
1. Increasing competition from major pharmaceutical players.
2. Regulatory changes may impact operational flexibility.
3. Price controls could reduce revenue margins.
4. Supply chain disruptions pose consistent operational risks.
1. Strong presence across high-demand therapeutic categories.
2. Robust nationwide distribution boosts market penetration.
3. Diversified brand portfolio supports stable revenues.
4. Growing healthcare demand enhances future scalability.
Corona Remedies operates across high-growth therapeutic areas such as women’s health, cardiology, pain management and urology, supported by a diverse portfolio of 71 brands. With a strong, pan-India field force and deep engagement with healthcare professionals, the company benefits from steady demand drivers and expanding healthcare needs. Its broad presence and established distribution network position it well for sustained long-term growth in the Indian pharmaceutical market.
- Companies
- Type
- Opening On
-
HRS Aluglaze
- SME
-
11th Dec
- Pre-Book
-
Pajson Agro India
- SME
-
11th Dec
- Pre-Book
-
ICICI Prudential Asset Management Co
- Mainboard
- 12th Dec
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Corona Remedies IPO opens from December 8, 2025 to December 10, 2025.
The size of Corona Remedies IPO is ₹655.37 Cr.
The price band of Corona Remedies IPO is fixed at ₹1008 to ₹1062 per share
To apply for Corona Remedies IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Corona Remedies. IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Corona Remedies IPO is of 14 shares and the investment required is ₹14,112.
The share allotment date of Corona Remedies IPO is December 11, 2025
The Corona Remedies IPO will likely be listed on December 15, 2025.
JM Financial Ltd is the book running lead managers for Corona Remedies IPO.
Corona Remedies IPO plans to utilise the raised capital from the IPO for:
1. The company will cover BRLMs fees and commissions.
2. It intends to pay registrar-related fees promptly.
3. Selling and processing charges will also be settled.
4. Advertising and marketing costs will be fully addressed.